New Data for Narmafotinib Presented at International Conference

Release Highlights:

• Additional data analysis from Amplia Therapeutics’ (ASX: ATX) Phase 1b/2a ACCENT trial in pancreatic cancer has been presented at the specialist scientific conference – the Keystone Meeting on the Tumor Microenvironment.
• The data analysis further confirms the promising activity of narmafotinib at the 400 mg dose.
• New preclinical data shows that narmafotinib enhances the activity of a drug that is used
  clinically to block the cancer-driving protein kRas in difficult-to-treat cancers, such as
  pancreatic cancer, lung cancer and colorectal cancer.